Introduction
Emerging evidence demonstrates that many successful vaccines induce antigen-specific T and B cell responses by activating the innate immune system 1 . This is most evident in live attenuated vaccines such as the yellow fever vaccine YF-17D 2 . In contrast, inactivated vaccines including subunit, conjugate, toxoid or carbohydrate vaccines typically stimulate sub-optimal immunity and often require adjuvants to enhance protective immunity especially in immune compromised populations such as the elderly or infants [3] [4] [5] [6] .
Vaccine adjuvants can enhance the magnitude, modulate the quality, breadth 7, 8 and persistence of an immune response [3] [4] [5] [6] 9 and help save on the dose of antigen required to TLR ligands represent an emerging new class of molecules with great potential as vaccine adjuvants [3] [4] [5] 8, 10 . Several TLR-dependent compounds are in advanced pre-clinical and clinical trials (CpG-ODN 10 , poly I-C/L-C 10 , GLA 14 ) and some have already been licensed for clinical use as adjuvants (MPL-AS04 13 ), or therapeutics (imidazoquilines 15 ). TLRs sense a wide range of pathogen-associated molecular patterns (PAMPs) from bacteria, viruses and parasites (reviewed in 16, 17 ). The non-toxic derivatives of LPS -MPL 18 or GLA 14 are detected by TLR4. TLR7 and 8 sense viral ssRNAs or small synthetic molecule compounds (R-837, R-848) 15, 19 . TLR9 recognizes unmethylated CpG motifs of bacterial and viral DNA 19, 20 .
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Interestingly, distinct TLRs are differentially expressed on different subsets of APCs.
Thus, in humans myeloid DCs (mDCs) express TLR4 and TLR8 3, 19 , and a subset of these are efficient at inducing cross-presentation of exogenously acquired antigens to CD8+ T cells 22, 23 , however a functional TLR8 is not expressed in mice. In contrast, human plasmacytoid DC (pDCs) express intracellular TLR7 and TLR9, which recognize viral and bacterial nucleic acids, and mediate production of type I IFNs 3, 19 , whereas in mice TLR7 and 9 are also expressed by CD8 neg mDC 3 . The discrepancies in TLR expression between mouse and human DCs may limit the translation of findings into clinical phase, thus highlighting the need for NHP and human trials.
Activation of immature DCs in the periphery by TLR ligands results in their maturation
and migration to the draining lymph nodes (LN), where they present antigen to naïve T cells, and initiate an immune response 1, 3, 21 . Neutrophils can also sense the TLRs, with exception of TLR3, and mediate rapid response by phagocytosis of infected cells release of NETs and production of chemokines to attract T and B cells to the site of antimicrobial invasion 24, 25 . Monocytes, in cooperation with neutrophils, also mediate and participate in early inflammatory response to microbes. However, distinct monocyte subtypes can be distinguished that differentially respond to the TLR stimuli [26] [27] [28] [29] [30] [31] [32] . The "classical" protocol. Total RNA sample quality was evaluated by spectrophotometer and RNA was reverse-transcribed using a High-Capacity cDNA Archive Kit Protocol (Applied Biosystems Inc.). The Quantitative Real-Time PCR Analysis Low Density Arrays for 96 genes were custom designed by Applied Biosystems (Table S1 ). All sequences were amplified using the Applied Biosystems 7900HT Sequence Detection System. Raw data were obtained by using SDS2.3 software (Applied Biosystems). Gene expression data were normalized relative to geometric mean of three housekeeping genes (18s, Actb, Gusb). Subsequently, Real-Time StatMinerTM software (Integromics Inc.) was used to perform a quality control for all runs, relative quantification delta-delta Ct analysis to calculate the fold differences between samples, and statistical significance analysis.
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Results

Intradermal injections of TLR-L induce rapid, systemic expansion of neutrophils, and reduced PBMC numbers
To assess the early systemic immune effects of TLR-adjuvants, we intradermally injected (upper, back left and right flanks of animal) rhesus macaques with one of the following: MPL (group 1), R-848 (group 2), and the CpG-ODN (group 3). We collected blood samples 12 days prior to injection (baseline) and then at 3 and 8 hours (hr) and days 1, 2, 3, 6 and 14 after injection ( Figure 1A ).
Injection of any of the TLR ligands mediated a rapid increase in absolute numbers of WBC as early as at 3 hr that lasted for at least 8 hr and declined to baseline values by day 1 ( Figure S1A ). This increase was mostly due to increased numbers of neutrophils ( Figure 1B-C) . Neutrophils comprised 45% ±4% (3299 ±319 cells/μl) of all WBCs at baseline ( Figure 1B-C) . However, within 3 hr of injection of R-848, MPL or CpG-ODN, respectively 92% ±3.2%, 76% ±10.3% and 82% ±3.8% of all WBC were neutrophils ( Figure 1C ). In fact, injection of any TLR-L induced a rapid increase in the absolute numbers of neutrophils within 3 hr, which declined substantially within 24 hr ( Figure   1B ). Notably, administration of the R-848 induced an increase of total neutrophils at 3 hr (21855 ±5701 cells/μl) and at 8 hr (22206 ±3607 cells/μl), significantly higher than other TLR agonists ( Figure 1B , Figure S1B ). Interestingly, there was a "secondary expansion" of neutrophils on day 14 in the animals that received CpG-ODN ( Figure 1B-C) . The kinetics of elevated frequencies and absolute numbers of neutrophils coincided with a decrease in frequencies and absolute numbers of PBMC in all the groups injected with TLR-L ( Figure 1B-C) .
In summary, injection of all three TLR-adjuvants induced an increase in the frequencies and absolute numbers of neutrophils. In fact, injection of R-848 induced highest expansion of neutrophils, which encompassed greater than 90% of WBC population at 3-8 hr. (Figure 2A ). Injection of MPL and CpG-ODN induced respectively a 2.4-and 2.5-fold increase of monocytes frequencies at 3 hr ( Figure 2A ). These elevated numbers of total monocytes were detectable for up to 2 days and decreased to baseline values after day 3 ( Figure 2A and data not shown). In the case of R-848 injection, despite an initial rapid reduction ( Figure   2A ), frequencies and numbers of total monocytes rapidly rebounded at 8 hr post R-848 injection and this increase was sustained for up to 6 days, reaching baseline levels by day 14 ( Figure 2A and data not shown).
Furthermore, we assessed the frequencies of monocyte sub-populations defined by the expression of the CD14 and CD16 surface markers [26] [27] [28] 30, 32 ++ subset was detectable throughout the whole study.
In contrast, injection of R-848, despite an initial rapid decline in the frequencies of total monocytes at 3 hr, yielded a striking increase in the frequencies of the "intermediate" 
R-848 and CpG-ODN trigger dendritic cells activation in blood
Further, we evaluated the frequency and activation of mDC and pDC ( Figure S2A Injection of CpG-ODN initially reduced the frequencies of mDC on day 1 that returned to initial magnitude on day 2 with further decline on days 3-14 ( Figure S2C ). Frequencies of pDCs expanded significantly between 3 hr and 2 days after CpG-ODN immunization, and declined to baseline levels on day 3 ( Figure S2B ). Injection of the CpG-ODN promoted enhanced expression of CCR7 on pDC ( Figure S2B ), however induced only limited activation of mDC ( Figure S2C ).
In summary, R-848 induced an initial decrease in magnitudes of peripheral pDC and mDC but mediated their high activation. In contrast, injection of CpG-ODN resulted in 
R-848 induces robust, systemic increase in inflammatory cytokines
We also evaluated serum cytokines (Figure 3) . Injection of R-848 stimulated robust secretion of IFN-α, IP-10, IL-6, and IL-1ra within 3-8 hr, significantly more than any other of the tested TLR-L (Figure 3) . Also, in animals that were injected with R-848 we In contrast to MPL, R-848 triggered a rapid (3hr) and robust transcription of several genes, including type I IFN stimulated genes (ISG) and chemokines, which returned to baseline levels by day 3 (Figure 4A-C) . This was consistent with the serum cytokine data (Figure 3) . Transcription of Il-6 was boosted at 3 hr and day 1 ( Figure 4A ). Interestingly, only injection of R-848 induced high expression of Il-8 on days 1 and 3 ( Figure 4A ).
Despite its potency, the transcriptional signature induced by R848 was short lived, with the expression of most genes declining to baseline levels by 3 days.
Injection of CpG-ODN also induced robust transcription of ISG on day 1 ( Figure 4A In summary, injection of R-848 induced a rapid (3 hr) and robust transcription of ISG, chemokine and cytokine genes that diminished after 1 day. In contrast, injection of CpG-ODN mediated up regulation of ISG and chemokine genes that was sustained for up to 6 days and induced up regulation of the Tnfrsf-17.
Distinct TLR-ligands differentially enhance the frequencies and activation of monocytes in the draining LN
Although cellular and cytokine changes in the blood provide a surrogate measure of adjuvant activity, assessment of changes in the draining LN provides a more direct measure of adjuvant action. We thus assessed changes in the frequencies and activation of APC subsets in the draining axillary LNs, after TLR-L injection. We injected the TLR- + cells at day 1 that expressed higher levels of CCR5 and CD80 until day 3.
TLR-ligands induce distinct patterns of enhancing the frequencies and activation of DCs in the draining LN
Furthermore we assessed the frequencies and activation phenotypes of mDC and pDC in the draining LN after injection of TLR-L.
Injection of MPL resulted in mobilization of the mDCs (6.2 fold), but only a modest expansion of pDC at day 3 ( Figure 6A -B). However, we did not observe an increase in expression of activation markers on either of the DC subset ( Figure 6A -B).
R-848 did not increase frequencies of either DC subsets, though the mDCs presented a highly activated phenotype by high expression of CD80 and CD86 and decrease in CCR5 on pDC on day 1, which returned to baseline levels by day 3 ( Figure 6A -B).
In contrast, CpG-ODN significantly augmented the frequencies of pDC on day 1 (5.5-fold, Figure 6A ). The high numbers of pDC were still evident on day 3 ( Figure 6A ). The augmented numbers of CD123 + cells (red) were also detectable in the sections of draining LN on days 1 and 3 post CpG-ODN injection ( Figure 6C ). Local pDCs diminished expression CCR5 on day 1, though no up-regulation of CCR7, CD80 or CD86 was detectable ( Figure 6A ). Immunization with CpG-ODN did not affect the frequencies of mDC in the draining LN however enhanced their expression of CD80 on days 1 and 3 ( Figure 6B ).
In summary, MPL induced expansion mDCs at day 3, but these cells did not express high levels of CD80 and CD86, relative to baseline. R-848 did not induce expansion of the DC subsets, however enhanced expression of CD80 and CD86 on mDCs at day 1. CpG-ODN enhanced numbers of pDCs on days 1 and 3.
Different TLR-adjuvants mediate distinct transcriptional signatures in LNs
To investigate the local molecular signatures mediated by injection of TLR-L, we examined the expression of selected genes in the draining LN cells ( Figure 7A ) using a similar approach as in PBMC (Figure 4 ).
Injection with CpG-ODN resulted in a robust ISG signature on day 1 that was further maintained until day 3 ( Figure 7B ). This high, CpG-ODN-mediated increase in expression of the ISG was consistent with enhanced frequencies of pDC in the LN on days 1 and 3 ( Figure 6A ). Injection of CpG-ODN also triggered expression of chemokine genes on day 1 with the high transcription of Cxcl-10 and Cxcl-11 still evident on day 3 ( Figure 7C ). CpG-ODN also enhanced expression of the complement genes that correlated with high frequency of the activated monocytes in the LN on day 1 ( Figure   5A ), similarly to the animals injected with MPL. 
Discussion
Recent studies have determined the early immune events induced by MF59, alum or CpG-ODN in-vivo, in mice [37] [38] [39] . However, to our knowledge there is no systematic evaluation of the early innate immune responses to TLR-Ls in non-human primates. In the current study, we performed a detailed analysis of the local and systemic effects of MPL, R-848 and CpG-ODN. The results indicate that the adjuvants differ vary considerably in the local and systemic responses they induce (summarized in Table 1 ).
All three adjuvants rapidly induced systemic changes in the cellular, transcriptional and cytokine responses in the blood. Thus, all TLR-L induced a rapid and robust expansion in the numbers of neutrophils in the blood (3-8 hrs), with R848 inducing the most robust increase. Neutrophils can quickly mobilize from the bone marrow to the blood in response to infections 24, 25 , and this is consistent with their increased numbers only hours after TLR-L injection ( Figure 1B-C) . Interestingly, we detected enhanced gene expression of IL-8 (Cxcl-8), a potent neutrophil chemoattractant, in the R848 group ( Figure 4A ). We also observed a "secondary" expansion of neutrophils in the animals injected with TLR9-L at day 14. This may reflect a sustained action of the PTO-stabilized CpG, which may persist at the site of injection and draining LNs and stimulate innate immune cells.
In addition to neutrophils, the three adjuvants differentially mobilized distinct blood monocyte sub-populations 27, 28, 30, 32 (Figure 2 Figure 2B -C). This distinct mobilization of monocytes may be caused by differential expression of various TLRs by distinct monocyte subsets ( Figure S4 ). In humans all subsets of monocytes were reported to express TLRs 4,7 and 8
32
, and Finally, the TLR-Ls used in the study were not formulated or mixed with any synthetic carrier; hence the innate immune responses induced by the TLR adjuvants are solely due to their sensing by TLRs, rather than other mechanisms involving the formulation. We injected 100 μg of unformulated MPL a dose that was previously reported to stimulate profound adjuvant effect in-vivo 9, 13, 43 . Though unformulated MPL is prone to form aggregates, which may decrease its bioavailability 44 , we detected mobilization of neutrophils and monocytes in periphery followed by the expansion of the latter in draining LN. Hence, even an unformulated, soluble MPL was able to stimulate potent systemic and local response, which is in agreement with previous reports in murine models 18, 43 . Furthermore we used 2 mg of the R-848 (resiquimod) a dose of the compound used previously in non human primates 9, 33, 45, 46 . R-848 mediated rapid inflammatory responses that resolved within 1-2 days after immunization, likely due to the instability of the compound in-vivo. This was consistent with elevated levels of the R-848 molecules in the serum, detectable only at 3 hr post injection ( Figure S5 Figure S2 . Statistical analysis indicates significant change of cell frequency relevant to the baseline, mean ± SEM, t-test, *p<0.05, **p<0.01, ***p<0.001. Activation and maturation profiles were measured by assessing the expression of the surface markers: CCR7, CCR5, CD80, CD80 at days 1 and 3 post TLR-L injection. Histograms represent the isotype control (gray), baseline at day -12 (black), day 1 (green) and day 3 (red) after TLR-L injection. Single, representative animal is shown for each experimental group. (C)
Immunohistochemistry staining was performed on frozen LN sections for evaluating the in-situ localization of APC in the animals injected with CpG-ODN (days 1 and 3). Cells were assessed by CD123 (red) and CD11c (green) staining, B cell follicles were visualized by CD20 staining (blue). One representative animal from the CpG-ODN experimental group is represented. For personal use only. on April 1, 2017. by guest www.bloodjournal.org From
